Pancreatic Cancer Research

ResearcherUniversity of PaduaActive in the last 2 years

Gaya Spolverato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7275-2573; OpenAlex author ID A5060542608. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers

Papers 9

  1. Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Last author DOI 10.1016/j.pan.2024.09.010↗
  2. Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers16234106↗
  3. Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.02.005↗
  4. Establishment of a human 3D pancreatic adenocarcinoma model based on a patient-derived extracellular matrix scaffold. Co-author DOI 10.1016/j.trsl.2022.08.015↗
  5. Does Extended Lymphadenectomy Help in Pancreatic Cancer? Co-author DOI 10.1245/s10434-022-11370-1↗
  6. Effects of the Exposure of Human Non-Tumour Cells to Sera of Pancreatic Cancer Patients. Co-author DOI 10.3390/biomedicines10102588↗
  7. Integrative medicine and surgery: what are the diet and supplement recommendations for someone with pancreatic cancer? First author DOI 10.21037/hbsn-20-863↗
  8. Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcop… First author DOI 10.1007/s11605-015-2835-y↗
  9. Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-015-4823-6↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isabella M. Frigerio · 3 shared papers, 2023–2024 · strength 0.55
  2. Giovanni Butturini · 3 shared papers, 2023–2024 · strength 0.55
  3. Quoc Riccardo Bao · 3 shared papers, 2023–2024 · strength 0.55
  4. Marzia Tripepi · 2 shared papers, 2023–2024 · strength 0.36
  5. Filippo Scopelliti · 2 shared papers, 2023–2024 · strength 0.35
  6. Paolo Regi · 2 shared papers, 2023–2024 · strength 0.35
  7. Alessandro Giardino · 2 shared papers, 2023–2024 · strength 0.35
  8. Roberto Girelli · 2 shared papers, 2023–2024 · strength 0.35
  9. Timothy Michael Pawlik · 3 shared papers, 2015–2022 · strength 0.32
  10. Hassan Aziz · 1 shared paper, 2022 · strength 0.22
  11. Jordan M. Cloyd · 1 shared paper, 2022 · strength 0.22
  12. Andrew A. Gumbs · 1 shared paper, 2021 · strength 0.22
  13. Elie K. Chouillard · 1 shared paper, 2021 · strength 0.22
  14. Marco Ventin · 1 shared paper, 2024 · strength 0.20
  15. Cristina Rosa Ferrone · 1 shared paper, 2024 · strength 0.20
  16. Darío Gregori · 1 shared paper, 2024 · strength 0.19
  17. Berina Šabanović · 1 shared paper, 2022 · strength 0.17
  18. Matteo Giulietti · 1 shared paper, 2022 · strength 0.17
  19. Francesco Piva · 1 shared paper, 2022 · strength 0.17
  20. Matteo Fassan · 1 shared paper, 2023 · strength 0.16
  21. Marco Agostini · 1 shared paper, 2023 · strength 0.16
  22. Francesca Sensi · 1 shared paper, 2023 · strength 0.16
  23. Faiz Gani · 1 shared paper, 2015 · strength 0.05
  24. Michail N. Mavros · 1 shared paper, 2015 · strength 0.05
  25. Aslam M. Ejaz · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.